Laboratory Corporation of Ameri – Consensus Indicates Potential 27.2% Upside
Laboratory Corporation of Ameri found using ticker (LH) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 350 and 215 calculating the average target price we see 305.15. With the stocks previous close at 239.91 this is indicating there is a potential upside of 27.2%. The 50 day MA is 240.54 while the 200 day moving average is 269.38. The company has a market capitalisation of $22,275m. Company Website: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,332m based on the market concensus. Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Laboratory Corporation of Ameri – Consensus Indicates Potential 27.2% Upside
Laboratory Corporation of Ameri found using ticker (LH) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 350 and 215 calculating the average target price we see 305.15. With the stocks previous close at 239.91 this is indicating there is a potential upside of 27.2%. The 50 day MA is 240.54 while the 200 day moving average is 269.38. The company has a market capitalisation of $22,275m. Company Website: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,332m based on the market concensus. Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.